Publication | Closed Access

Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months

VaccinologyVaccinationVaccine DevelopmentLyme Disease VaccineImmunologyRecombinant Outer-surface ProteinInfection Control3-Dose SchedulePolyvalent VaccineMedicineVaccine ResearchVaccine DesignTick-borne Disease